|会社名||AngioDynamics Inc （アンジオダイナミクス）|
|分野（sector）||Health Care ヘルスケア|
|業種||医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care）|
|概要||事業概要 アンジオダイナミクス(AngioDynamics Inc.)は血管アクセス、末梢血管疾患の治療、腫瘍学および外科手術環境での使用のために、専門の医療提供者によって使用される医療、外科と診断装置を設計、製造および販売する。同社のデバイスは低侵襲イメージガイド付きの手順に使用される。同社は、末梢血管、血管アクセスおよび腫瘍・外科の3つの製品グルーピング製品を提供する。同社の末梢血管製品には、流体管理、静脈、血栓管理等の主要製品が含まれる。同社のBioFlo製品は、Endexo技術を血管アクセス製品の製造・設計に組み込む。同社の腫瘍・外科製品にはマイクロ波アブレーション製品、ラジオ波アブレーション(RFA)、NanoKnife製品ラインなどを含む。 アンジオダイナミクスは米国の医療機器メ―カ―。末梢血管疾患の治療や手術に使用される医療機器の開発、製造、販売を行う。同社の製品は高周波焼灼術用機器、NanoKnifeの他、血管アクセス製品、血管造影製品、透析製品、血管形成術製品、排水製品、血栓溶解製品、塞栓製品、静脈製品や腎臓治療の製品など。本社はニューヨーク州レ―サム。 AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.|
|本社所在地||14 Plaza Drive Latham NY 12110 USA|
|代表者氏名||Howard W. Donnelly ハワード・W・ドネリー|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the three months ended 31 August 2018 AngioDynamics Inc. revenues decreased less than 1% to $85.3M. Net loss increased from $35K to $469K. Revenues reflect Vascular Access segment increase of 2% to $23.8M Peripheral Vascular segment increase of less than 1% to $50M International segment increase of 7% to $17.7M also reflect Oncology/Surgery segment decrease of 6% to $11.6M United States segment decrease of 2% to $67.7M.|
AngioDynamics, Inc. 2023 Q3 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2023/03/30 18:10:03 Seeking Alpha
The following slide deck was published by AngioDynamics, Inc.
AngioDynamics Inc. (ANGO) Q3 2023 Earnings Call Transcript | AlphaStreet 2023/03/30 16:39:31 AlphaStreet
AngioDynamics Inc. (NASDAQ: ANGO) Q3 2023 earnings call dated Mar. 30, 2023
AngioDynamics, Inc. (ANGO) Q3 2023 Earnings Call Transcript 2023/03/30 14:59:04 Seeking Alpha
AngioDynamics, Inc. (NASDAQ:NASDAQ:ANGO) Q3 2023 Earnings Call Transcript March 30, 2023 8:00 AM ETCompany ParticipantsJim Clemmer - CEOSteve Trowbridge - CFOConference Call…
SCYNEXIS, Palisade top healthcare gainers; AngioDynamics, Avidity lead losers'' pack 2023/03/30 14:02:34 Seeking Alpha
SCYNEXIS (SCYX) +61%. Palisade Bio (PALI) +33%. AngioDynamics (ANGO) -28%. Avidity Biosciences (RNA) -21%.
ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9% | AlphaStreet 2023/03/30 12:53:45 AlphaStreet
AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter of 2023 when the medical device maker''s revenues increased by 9%. The company also provided guidance for fiscal 2023. AngioDynamics reported an adjusted net loss of $0.03 per share for the third quarter, compared to earnings of $0.03 per share in […]
A Mostly Clean Quarter Drives A Better Valuation For AngioDynamics 2023/01/06 21:21:49 Seeking Alpha
AngioDynamics posted a pretty clean fiscal Q2 that was a little better than the sell-side expected. Click here to read our analysis of ANGO stock.
AngioDynamics Shares Up 11% on 2Q Sales Gain 2023/01/05 16:46:00 MarketWatch
By Kathryn Hardison Shares of AngioDynamics Inc. increased 11% to $15.07 on Thursday after the company reported a boost to second-quarter sales. Shares…
AngioDynamics, Inc. 2023 Q2 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2023/01/05 16:18:19 Seeking Alpha
The following slide deck was published by AngioDynamics, Inc.
AngioDynamics, Inc. (ANGO) Q2 2023 Earnings Call Transcript 2023/01/05 16:17:02 Seeking Alpha
AngioDynamics, Inc. (NASDAQ:NASDAQ:ANGO) Q2 2023 Earnings Conference Call January 05, 2023, 08:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive…
AngioDynamics Non-GAAP EPS of $0.01 beats by $0.02, revenue of $85.4M beats by $1.02M, reaffirms fiscal year 2023 outlook 2023/01/05 12:20:17 Seeking Alpha
AngioDynamics press release (ANGO): Q2 Non-GAAP EPS of $0.01 beats by $0.02.Revenue of $85.4M (+9.1% Y/Y) beats by $1.02M.Fiscal Year 2023 Financial Guidance: Management is…
Interventional Radiology Devices Market to See Huge Growth by 2027 : Guerbet, Medtronic, Biotronik 2022/08/08 18:25:00 SBWire
New Jersey, USA -- ( SBWIRE ) -- 08/08/2022 -- The latest study released on the Global Interventional Radiology Devices Market by AMA Research evaluates market size, trend, and forecast to 2027. The Interventional Radiology Devices market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key Players in This Report Include: Abbott (United States), B. Braun (Germany), Boston Scientific (United States), Koninklijke Philips (Netherlands), Cardinal Health (United States), Medtronic (Ireland), Alvimedica (Turkey), Guerbet (France), Angiodynamics (United States), Balton (Poland) and Brosmed Medical (China). Additionally, following companies can also be profiled that are part of our coverage like Biosensors (Switzerland), Biotronik (Germany), Cook Medical (United States) and Endocor (Germany) Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.advancemarketanalytics.com/sample-report/78326-global-interventional-radiology-devices-market Definition: Image-guided surgery seems to be what interventional radiology is all about.
AngioDynamics to Present at the Canaccord Genuity Growth Conference 2022/08/03 20:01:00 Business Wire
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference at 2:00 p.m. ET on Wednesday, August 10, 2022. A live webcast
AngioDynamics: Growth Is Encouraging, But Margins Still A Work In Progress (NASDAQ:ANGO) 2022/07/14 03:32:08 Seeking Alpha
AngioDynamics posted better sales growth in FQ4''22 as elective procedure counts continue to rebound, but margin pressures continue to weigh significantly.
Raymond James Cuts Price Target On AngioDynamics 2022/07/13 18:51:15 Benzinga
Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO ) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EV/sales, Raymond James believes ANGO is undervalued given its growth profile and expects the multiple to expand with continued execution, supporting the Strong Buy rating. The revenue momentum is real and will carry into F23 (guide of 8-10% growth), the analyst wrote. He views back-order fulfillment as a … Full story available on Benzinga.com